CLINICAL & PIPELINE·Drug Approval
FDA Approves Ascendis Pharma's YUVIWEL (NAVEPEGRITIDE) as New Molecular Entity with Orphan Designation
Ascendis Pharma Endocrinology, Inc. has secured FDA approval for YUVIWEL (NAVEPEGRITIDE), a New Molecular Entity (NDA219164) with Orphan Drug designation, on February 27, 2026. This strategic approval marks a significant market entry in systemic hormones, offering a novel therapeutic option and signaling Ascendis's expanding presence in specialized pharmaceutical markets.
90-Day Activity